Boehringer starts enrolment for paediatric trial of nintedanib
Boehringer will assess the dose-exposure and safety of nintedanib in paediatric patients. Credit: Madras150.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more